[Federal Register Volume 63, Number 127 (Thursday, July 2, 1998)]
[Notices]
[Pages 36235-36236]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-17594]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[INFO-98-22]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call the CDC Reports
Clearance Officer on (404) 639-7090.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques for other
forms of information technology. Send comments to Seleda Perryman, CDC
Assistant Reports Clearance Officer, 1600 Clifton Road, MS-D24,
Atlanta, GA 30333. Written comments should be received within 60 days
of this notice.
Proposed Project
1. Gonococcal Isolate Surveillance Project (GISP) (0920-0307)--
Extension--The Division of STD Prevention, National Center for HIV, STD
and TB Prevention (NCHSTP) is requesting a 3-year extension of OMB
clearance to continue the Gonococcal Isolate Surveillance Project
(GISP). The objectives of GISP are: (1) To monitor trends in
antimicrobial susceptibility of strains of Neisseria gonorrhoeae in the
United States; and (2) to characterize resistant isolates. GISP
provides critical surveillance for antimicrobial resistance, allowing
for informed treatment recommendations. GISP was begun in 1986 as a
voluntary surveillance project and now involves 5 regional laboratories
and 26 publicly funded sexually transmitted disease clinics around the
country. The STD clinics submit up to 25 gonococcal
[[Page 36236]]
isolates per month to the regional laboratories, which measure
susceptibility to a panel of antibiotics. Limited demographic and
clinical information corresponding to the isolates are submitted
directly by the clinics to CDC.
During 1986-1997, GISP has demonstrated the ability to effectively
achieve its objectives. The recent emergence of resistance to
fluoroquinolones, commonly used therapies for gonorrhea, has been
identified through GISP and makes ongoing surveillance critical. Data
gathered through GISP are used to alert the public health community to
changes in antimicrobial resistance in N. gonorrhoeae which may impact
treatment choices, and to guide recommendations made in CDC's STD
Treatment Guidelines, which are published every several years. There is
no cost to the respondents.
----------------------------------------------------------------------------------------------------------------
No. of
Respondent No. of responses/ Avg. burden Total burden
respondents respondents (in hrs.) (in hrs.)
----------------------------------------------------------------------------------------------------------------
Laboratory...................................... 5 1056 1 5312
Clinic.......................................... 26 204 0.166 8846
---------------------------------------------------------------
Total....................................... .............. .............. .............. 6196
----------------------------------------------------------------------------------------------------------------
2. Tuberculosis Statistics and Program Evaluation Activity, Contact
Follow-up (CDC 72.16) and Completion of Preventive Therapy (CDC
72.21)--(0920-0026)--Extension--The National Center for HIV, STD and TB
Prevention (NCHSTP)--Tuberculosis (TB) is transmitted when contagious
TB patients aerosolize Mycobacterium tuberculosis and susceptible
persons (i.e., ``contacts'') are exposed. Some contacts are especially
endangered by TB if they become infected--children younger than 5 years
old, and anyone with an illness that weakens the immune system (e.g.,
the acquired immunodeficiency syndrome, AIDS). The prompt evaluation of
all contacts is crucial for finding early TB cases and latent
infections. For latent TB infections, treatment with isoniazid
preventive therapy can prevent new TB cases from developing.
Evaluation, follow-up, and preventive therapy for contacts comprise the
most efficient approach for finding and treating recent TB infections
and preventing future cases. Therefore, it is one of the highest
priorities for the national TB control strategy, second only to finding
and treating contagious cases. The local and the state TB control
programs and CDC use Contact Follow-up (CDC 72.16) and Completion of
Preventive Therapy (CDC 72.21) to measure progress in achieving the
national goals for performance in these areas. There is no cost to the
respondents.
----------------------------------------------------------------------------------------------------------------
No. of
No. of responses/ Avg. burden/ Total burden
Report respondents respondent (in response (in (in hrs.)
hrs.) hrs.)
----------------------------------------------------------------------------------------------------------------
Contact Follow-up (1996),...................... 103 2 .5 103
Completion of Preventive Therapy (1995)........ 103 2 1 206
Total...................................... .............. .............. ............... 309
----------------------------------------------------------------------------------------------------------------
Dated: June 26, 1998.
Charles W. Gollmar,
Acting Associate Director for Policy, Planning and Evaluation,Centers
for Disease Control and Prevention (CDC).
[FR Doc. 98-17594 Filed 7-1-98; 8:45 am]
BILLING CODE 4163-18-P
